Who Owns Biomea Fusion Company?

Biomea Fusion Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Biomea Fusion?

Biomea Fusion's ownership structure is shaped by its recent public offering in June 2025, introducing common stock and warrants. Founded in 2017, this clinical-stage biopharmaceutical company focuses on irreversible small molecule inhibitors for genetic cancers and metabolic diseases.

As of August 2025, Biomea Fusion is publicly traded on NASDAQ under BMEA, with a market cap around $108.90 million. The company, employing over 100 individuals by late 2024, is dedicated to advancing its pipeline of covalent small molecule drugs, including its Biomea Fusion PESTEL Analysis.

Biomea Fusion, Inc. was co-founded in August 2017 by Thomas Butler and Ramses Erdtmann. They brought valuable experience from their prior work together at Pharmacyclics, with Butler also having a background in investor relations and medicinal chemistry. The company began as Biomea Fusion, LLC, later becoming a corporation on December 18, 2020.

Founding Year

Biomea Fusion was established in August 2017. This marked the beginning of its journey in the biotechnology sector.

Early Funding Milestone

The company secured a significant Series A financing round in October 2020. This round raised $56 million, crucial for advancing its preclinical pipeline.

Key Early Investors

Prominent firms like Cormorant Asset Management, OrbiMed, Janus Henderson Investors, and Rock Springs Capital were key early backers. Their investment provided essential capital for the company's development.

Corporate Conversion

The company transitioned from a Limited Liability Company (LLC) to a corporation. This conversion to Biomea Fusion, Inc. occurred on December 18, 2020.

Founder's Current Stake

As of August 13, 2025, Thomas Butler holds 4.68 million shares, representing 7.86% of the company. This makes him the largest individual shareholder.

Ramses Erdtmann's Beneficial Ownership

Rainer M. Erdtmann beneficially owns 2,975,224 shares as of August 13, 2025. This equates to approximately 5.2% of the outstanding class, including exercisable options and shares held through trusts.

The initial ownership structure of Biomea Fusion, while not publicly detailed at its inception, saw the founders retaining significant stakes. This early backing from institutional investors was instrumental in propelling the company's preclinical research forward. Understanding the Marketing Strategy of Biomea Fusion can also provide context on how these early investments were leveraged.

Biomea Fusion Ownership Overview

The ownership of Biomea Fusion is primarily held by its founders and early institutional investors. As of mid-2025, key individuals maintain substantial stakes, reflecting their foundational roles and ongoing commitment.

• Thomas Butler is the largest individual shareholder with 7.86% ownership as of August 13, 2025.
• Rainer M. Erdtmann holds approximately 5.2% of the company's outstanding class as of August 13, 2025.
• The company secured $56 million in Series A funding in October 2020.
• Early investors include Cormorant Asset Management, OrbiMed, Janus Henderson Investors, and Rock Springs Capital.
• Biomea Fusion was co-founded in August 2017.

Biomea Fusion SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Biomea Fusion, Inc. became a publicly traded entity on April 16, 2021, listing on the NASDAQ Global Select Market under the ticker BMEA. The company's initial public offering (IPO) raised $153.0 million, but its market capitalization has since seen a significant decline. This evolution from a private to a public company has reshaped its ownership landscape, introducing a broader base of investors.

The ownership structure of Biomea Fusion is largely dominated by institutional investors, who collectively held 48.17% of the company's shares as of August 2025. Key institutional stakeholders include Fmr Llc, holding 9.53% as of March 2025, and Heights Capital Management, Inc., with 7.80% as of June 2025. Cormorant Asset Management, LP also maintains a significant stake of 6.26% as of June 2025. Insider ownership, representing shares held by directors and executives, accounts for 28.91% of the company. Notable individual shareholders include co-founder Thomas Andrew Butler, who possesses 7.86% of the company's stock, and co-founder Rainer M. Erdtmann, holding approximately 5.2% as of August 13, 2025. Retail investors make up the remaining 22.92% of Biomea Fusion's ownership. This concentration of ownership among large financial entities highlights their influence on the company's strategic direction and governance.

Understanding Biomea Fusion's Stakeholders

Biomea Fusion's ownership is a mix of institutional, insider, and retail investors. Understanding these groups is crucial for grasping the company's dynamics.

• Institutional investors hold a significant portion, influencing strategic decisions.
• Insider ownership reflects the commitment of the executive team and board.
• Retail investors represent the public's stake in the company's performance.
• The evolution of Biomea Fusion's ownership reflects its journey as a publicly traded entity.

Biomea Fusion PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The strategic direction of Biomea Fusion is currently guided by its Board of Directors, which saw a significant leadership change in March 2025. Dr. Michael J.M. Hitchcock is the Interim Chief Executive Officer, and Rainer M. Erdtmann serves as President and Chief Operating Officer. The board also includes Julianne Averill, Sumita Ray, J.D., Dr. Eric Aguiar, M.D., and Dr. Elizabeth Faust, PhD.

Biomea Fusion operates with a one-share-one-vote structure for its common stock, meaning each share grants its holder one vote on all matters, including director elections. Cumulative voting rights are not available, allowing a simple majority of voting shares to elect all directors. However, certain critical changes, such as amendments to the certificate of incorporation regarding the classified board or director liability, require a supermajority vote of 66-2/3% of the total voting power. While no specific individuals are publicly designated with special voting rights, key insiders like Thomas Butler, holding 7.86%, and Ramses Erdtmann, with 5.2%, possess considerable influence. Mr. Erdtmann also shares voting and dispositive power over shares held by affiliated entities like Point Sur Investors, LLC and Point Sur Investors Fund I, L.P. The company has not experienced public proxy battles or activist campaigns, but the recent CEO transition in March 2025 marked a notable governance event impacting decision-making processes. Understanding the Revenue Streams & Business Model of Biomea Fusion can provide further context on the company's operational direction and the board's oversight.

Key Voting Power Dynamics

The voting structure at Biomea Fusion grants significant influence to major shareholders. Key individuals and affiliated entities hold substantial stakes, impacting corporate decisions.

• One-share-one-vote system for common stock.
• No cumulative voting rights for directors.
• Majority shareholders can elect all directors.
• Supermajority vote (66-2/3%) required for certain charter amendments.
• Significant influence held by insiders like Thomas Butler (7.86%) and Ramses Erdtmann (5.2%).

Biomea Fusion Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Biomea Fusion has undergone significant changes in its leadership and strategic focus over the past few years, impacting its ownership trends. A key leadership transition occurred in March 2025, with a co-founder stepping down as CEO and Chairman, leading to an interim CEO appointment. This period also saw a strategic pivot towards core therapeutic areas and operational adjustments.

The ownership structure of Biomea Fusion has been influenced by recent capital-raising activities and shifts in institutional investor holdings. A public offering in June 2025, which aimed to raise around $40 million, resulted in a substantial increase in the total shares outstanding, growing by 64.3% in the year leading up to August 2025. This dilution has affected existing shareholders. While institutional investors held approximately 48.17% of the company in 2025, some significant holders like Millennium Management LLC and Baker Bros. Advisors LP notably decreased their stakes in the fourth quarter of 2024. The company's market capitalization has seen a considerable decline, dropping by 77.73% since its IPO in April 2021, standing at $108.90 million as of August 22, 2025. These trends reflect a dynamic ownership landscape shaped by strategic decisions and market performance.

Leadership Changes

Co-founder Thomas Butler stepped down as CEO and Chairman on March 25, 2025. Dr. Michael J.M. Hitchcock became Interim CEO.

Strategic Reorientation

The company officially shifted its focus to diabetes and obesity medicines in Q1 2025, discontinuing oncology programs.

Capital Infusion and Dilution

A public offering on June 17, 2025, raised approximately $40 million, leading to a 64.3% increase in shares outstanding.

Institutional Investor Activity

Major institutional investors reduced their holdings in Q4 2024, while institutional ownership stood at 48.17% in 2025.

Biomea Fusion Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔